Details of the Drug Reposition

General Information of This Drug (ID: DM4YMIS)

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

7 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Leukemia	DISNAKFL	N.A.	Approved	[1]
Desmoplastic small round cell tumor	DISLI2ME	N.A.	Approved	[2]
Childhood myelodysplastic syndrome	DISMN80I	N.A.	Approved	[2]
Acute myelogenous leukaemia	DISCSPTN	2A41	Approved	[1]
Lung cancer	DISCM4YA	2C25.0	Approved	[3]
Cutaneous melanoma	DIS3MMH9	2C30	Approved	[4]
Renal cell carcinoma	DISQZ2X8	2C90	Approved	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Indications(s)

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Phase 2	[5]
------------------------------------------------------------------------------------

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Metastatic melanoma	DISSL43L	2E2Z	Discontinued in Phase 2	[6]
------------------------------------------------------------------------------------

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Gastric cancer	DISXGOUK	2B72	Investigative	[2]
Colon cancer	DISVC52G	2B90.Z	Investigative	[7]
------------------------------------------------------------------------------------

References

1	Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep;46(3):446-514.
2	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3	Targeting interleukin-1 and inflammation in lung cancer. Biomark Res. 2022 Jan 27;10(1):5.
4	Aldesleukin. 2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
5	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
6	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
7	Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008 Jul 1;14(13):4192-9.